Sharechat Logo

Daily ShareChat: Ebos Group

By Jenny Ruth

Thursday 4th March 2010

Text too small?
 Jenny Ruth

Medical supplies company Ebos' 37.6% rise to $11.7 million in first-half net profit was well ahead of his $9.6 million forecast, says Selwyn Blinkhorne, an analyst at Craigs Investment Partners.

The increase mostly reflected operating efficiencies and technology and both gross earnings before interest, tax, depreciation and amortisation (EBITDA) and EBIT margins rose about 50 basis points while interest costs were 29% lower with net debt falling from $67.9 million in the previous first half to $29 million.

"Our forecasts now reflect the higher margins being achieved and also a more modest seasonal trading skew towards the second half of the year," Blinkhorne says. He has raised his forecast earnings for the year ending June from $23.3 million to $24 million and his forecast for the year ending June 2011 from $25.1 million to $26 million.

He expects Ebos will continue to grow through acquisitions and has factored in "relatively modest acquisitions" of $10 million each in 2011 and 2013.

Blinkhorne has also raised his valuation and target price from $5.99 to $6.64 to reflect the expected higher earnings.

"The key risks to our target price relates to margins and revenues being subject to pressure from public health sector spending initiatives and constraints."


BROKER CALL:  Craigs Investment Partners rate Ebos as buy (raised from hold).




  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions